Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822416 · ClinicalTrials.gov registry record · Phase 2
Treating Smokers With Mental Illness
A Phase 2 study of Schizophrenia and Major Depressive Disorder, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT03822416: Completed Phase 2 study of Schizophrenia and Major Depressive Disorder, sponsored by University of Minnesota.
NCT03822416 is a Phase 2 study of Schizophrenia and Major Depressive Disorder that has completed, run by University of Minnesota. The registered enrollment target is 38 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03822416, a Phase 2 study of Schizophrenia and Major Depressive Disorder, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to assist smokers in cutting back on and quitting smoking over the course of six months.
Primary Outcome
To determine the number of patients in the intervention and control conditions who achieve 7-day point prevalence abstinence at 8 weeks and 6 months after enrollment.
Conditions Studied
Interventions
- DRUG Nicotine patch
- BEHAVIORAL Therapy
- OTHER Information
- DRUG Nicotine lozenge
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 2 |
What the finished NCT03822416 record still lists
NCT03822416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower).
The record links to 8 conditions, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Nicotine patch is the first listed.
NCT03822416 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03822416 about?
NCT03822416 is a clinical study titled "Treating Smokers With Mental Illness". This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to assist smokers in cutting back on and quitting smoking over the course of si...
What is the current status of trial NCT03822416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2019-03-01. Estimated completion is 2020-05-04.
What conditions does trial NCT03822416 study?
This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Smoking Cessation, Cigarette Smoking, Psychotic Disorders.
What interventions are being tested in trial NCT03822416?
The interventions under investigation include: Nicotine patch (DRUG), Therapy (BEHAVIORAL), Information (OTHER), Nicotine lozenge (DRUG).
Who is sponsoring clinical trial NCT03822416?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03822416 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03822416's enrollment target sits among peer trials
38 246th of 315 higher than 66 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI